Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Novartis AG's share price for the quarter that ended in Mar. 2026 was CHF119.3. Novartis AG's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 1,908 Mil. Therefore, Novartis AG's market cap for the quarter that ended in Mar. 2026 was CHF227,643 Mil.
Novartis AG's quarterly market cap
increased
from Sep. 2025 (CHF192,685 Mil) to Dec. 2025 (CHF209,439 Mil) and
increased
from Dec. 2025 (CHF209,439 Mil) to Mar. 2026 (CHF227,643 Mil).
Novartis AG's annual market cap
increased
from Dec. 2023 (CHF172,864 Mil) to Dec. 2024 (CHF174,736 Mil) and
increased
from Dec. 2024 (CHF174,736 Mil) to Dec. 2025 (CHF209,439 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Novartis AG's Enterprise Value for Today is CHF247,273 Mil.
Novartis AG (XSWX:NOVNEE) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Novartis AG Market Cap Related Terms
Novartis AG Market Cap Historical Data
* Premium members only.
The historical data trend for Novartis AG's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:NOVNEE vs LLY, JNJ, ABBV: Market Cap Comparison
For the Drug Manufacturers - General subindustry, Novartis AG's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Novartis AG Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Novartis AG's Market Cap distribution charts can be found below:
* The bar in red indicates where Novartis AG's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Novartis AG's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Novartis AG (XSWX:NOVNEE) has a Market Cap of CHF228,062 Mil as of Jul. 01, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Novartis AG and its competitors. According to the industry distribution chart, Novartis AG ranks #6 out of 1022 companies in the Drug Manufacturers industry, placing it in the top 0.59999999999999%.
Is Novartis AG's Market Cap too high?
Novartis AG's current Market Cap is CHF228,062 Mil. Based on the distribution chart, Novartis AG ranks #6 out of 1022 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Novartis AG has a GF Score™ of 83/100, reflecting its overall financial health beyond just this single metric.
How does Novartis AG's Market Cap compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Novartis AG ranks #6 out of 1022 companies for Market Cap. This places Novartis AG in the top 1% of its industry — outperforming the majority of peers. The industry median Market Cap is 210.16. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 210.16, based on 1,022 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Novartis AG and its competitors. For the Drug Manufacturers industry, the median Market Cap is 210.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Novartis AG's current Market Cap is CHF228,062 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novartis AG stock overvalued right now?
Novartis AG (XSWX:NOVNEE) has a current Market Cap of CHF228,062 Mil. The stock's GF Value™ is CHF97.10, compared to a current price of CHF119.30 — trading 22.9% above its estimated fair value. The current Market Cap is CHF228,062 Mil. Novartis AG's overall GF Score™ is 83/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Novartis AG (XSWX:NOVNEE), the current Market Cap is CHF228,062 Mil as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Novartis AG (XSWX:NOVNEE) Overvalued in 2026?
Based on GuruFocus' analysis, Novartis AG stock appears to be overvalued.
The current stock price of CHF119.30 is trading 22.9% above its estimated GF Value™ of CHF97.10.
Key valuation signals for XSWX:NOVNEE:
Market Cap: CHF228,062 Mil
GF Value™: CHF97.10 vs. price of CHF119.30 (22.9% above fair value)
No single metric tells the full story. See the XSWX:NOVNEE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, respiratory, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.
83GF Score
Get the complete analysis for XSWX:NOVNEE
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:NOVNEE has been successfully added to your 
